TB smokers may experience increased metabolite synthesis, potentially necessitating dosage adjustments. Furthermore, adequate dose monitoring is even more important when considering that clofazimine is itself, at low concentration, a weak inducer of CYP3A4, but at therapeutic levels shows inhibitory properties. Here, CYP3A4 is linked to tuberculosis.